Moderna's 750 Custom GPTs Are Redesigning Drug Development

Two months. Seven hundred and fifty custom GPTs. Moderna’s partnership with OpenAI isn’t a press release gimmick—it’s a full-scale operational rewiring that’s already producing numbers most enterprise AI rollouts can only dream about. Since adopting ChatGPT Enterprise, 40% of weekly active users at the biotech firm have built their own GPTs, and the average employee now clocks 120 conversations with the tool every single week. That’s not experimentation. That’s dependency.

Moderna’s AI chief Brice Challamel didn’t mince words when his team ran the numbers. They tested mChat (their homegrown internal chatbot), Microsoft Copilot, and ChatGPT Enterprise side by side. “We found out that the net promoter score of ChatGPT Enterprise was through the roof,” Challamel said. Game over. The company doubled down on OpenAI’s platform and never looked back. The results suggest they made the right call—2,000 employees now actively participate in an internal AI forum weekly, swapping prompts and use cases across every business function from legal to manufacturing.

But the flashy adoption stats only tell half the story. The real signal is Dose ID, a GPT pilot designed to review clinical data, integrate large datasets, and serve as an analytical sidekick for clinical study teams. Moderna’s pipeline is ambitious—up to 15 new mRNA products in five years, spanning RSV vaccines to individualized cancer treatments—and that timeline doesn’t work if clinical trials crawl at traditional pharma speed. Dose ID is the kind of bespoke tool that moves the needle, not just a chatbot for summarizing meeting notes.

Moderna’s approach to change management deserves more attention than it’ll probably get. CEO Stéphane Bancel and the executive committee didn’t just send a memo. They ran in-person trainings, built AI learning companions, ran a prompt contest to identify 100 internal generative AI champions, and hosted town halls. “Using AI to teach AI was key to our success,” said Moderna executive Mark Miller. The company hit its absurdly aggressive target: 100% adoption and proficiency among digital-enabled staff within six months. Most enterprises struggle to get 30% of employees to open a new tool once. Moderna lit a fire instead of filling a bucket, and now it’s spreading faster than even the optimists predicted.